Sustained hematologic remission after discontinuation of sutimlimab treatment in patients with cold agglutinin disease
Blood Adv
.
2023 May 23;7(10):1987-1990.
doi: 10.1182/bloodadvances.2022008574.
Authors
Georg Gelbenegger
1
,
Ulrich Jäger
2
,
Michael Fillitz
3
,
Christian Schörgenhofer
1
,
Christian Sillaber
2
,
Bernd Jilma
1
Affiliations
1
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
2
Division of Hematology and Hemostasis, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
3
Department of Medicine, Hanusch Krankenhaus, Vienna, Austria.
PMID:
36322823
PMCID:
PMC10189382
DOI:
10.1182/bloodadvances.2022008574
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't
MeSH terms
Anemia, Hemolytic, Autoimmune* / drug therapy
Antibodies, Monoclonal, Humanized
Humans
Substances
sutimlimab
Antibodies, Monoclonal, Humanized